Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient

被引：7
|
作者：
Ito, Munehiro [1 ]
Kanda, Shintaro [1 ]
Yoshida, Tatsuya [1 ]
Okuma, Yusuke [1 ]
Jo, Hitomi [1 ]
Fukuhara, Suguru [2 ]
Maeshima, Akiko Miyagi [3 ]
Ohe, Yuichiro [1 ]
机构：
[1] Natl Canc Ctr, Dept Thorac Oncol, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan
[2] Natl Canc Ctr, Dept Hematol, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan
[3] Natl Canc Ctr, Dept Diagnost Pathol, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan
来源：
LUNG CANCER | 2020年 / 146卷
关键词：
immune-related thrombocytopenia; pembrolizumab; eltrombopag olamine; rituximab; non-small cell lung cancer; PURPURA;
D O I：
10.1016/j.lungcan.2020.05.015
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Objectives: Immune checkpoint inhibitors (ICIs) have shown antitumor activity against a wide variety of malignancies. ICI-induced immune-related thrombocytopenia is a rare immune-related adverse event (irAE). Little is known about the treatment of refractory immune-related thrombocytopenia in non-small cell lung cancer (NSCLC) patients treated with pembrolizumab. Results: We report the case of a patient with advanced NSCLC complicated by pembrolizumab-induced refractory immune-related thrombocytopenia who showed remarkable improvement in the thrombocytopenia in response to eltrombopag olamine treatment. Conclusion: Eltrombopag olamine can be a viable treatment option for refractory pembrolizumab-induced immune-related thrombocytopenia in an NSCLC patient.
引用
收藏
页码：362 / 365
页数：4
相关论文
共 50 条
  • [31] Case Report: Nintedanib for Pembrolizumab-Related Pneumonitis in a Patient With Non-Small Cell Lung Cancer
    Xie, Xiao-Hong
    Deng, Hai-Yi
    Lin, Xin-Qing
    Wu, Jian-Hui
    Liu, Ming
    Xie, Zhan-Hong
    Qin, Yin-Yin
    Zhou, Cheng-Zhi
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [32] Pembrolizumab for the treatment of non-small cell lung cancer
    Lim, Sung Hee
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (03) : 397 - 406
  • [33] Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer
    Morgensztern, Daniel
    Herbst, Roy S.
    CLINICAL CANCER RESEARCH, 2016, 22 (15) : 3713 - 3717
  • [34] Long-Term Survival With Pembrolizumab Re-administration After Pseudo-Progression With Immune-Related Interstitial Lung Disease in a Patient With Non-small Cell Lung Cancer
    Nakashima, Koki
    Demura, Yoshiki
    Akai, Masaya
    Ishizuka, Tamotsu
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (07)
  • [35] Predictors of Immunotherapy Efficacy in Metastatic Non-Small Cell Lung Cancer: Lung Immune Prognostic Index and Immune-Related Toxicity
    Pellitero, Alba Moratiel
    Garcia, Maria Zapata
    Ruiz, Marta Gascon
    Arbones-Mainar, Jose Miguel
    Prado, Rodrigo Lastra del
    Isla, Dolores
    WORLD JOURNAL OF ONCOLOGY, 2024, 15 (02) : 223 - 238
  • [36] Vogt-Koyanagi-Harada Syndrome Induced by Pembrolizumab in a Patient with Non-Small Cell Lung Cancer
    Tamura, Tomoki
    Akimoto, Etsuko
    Matsumoto, Chiaki
    Mori, Syunta
    Nishi, Tatuya
    Kudo, Kennichiro
    Kuyama, Syouichi
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : 1606 - 1607
  • [37] Dramatically changed immune-related molecules as early diagnostic biomarkers of non-small cell lung cancer
    Ye, Xiangdong
    Zhang, Ni
    Jin, Yanxia
    Xu, Bo
    Guo, Chanyuan
    Wang, Xueqing
    Su, Yanting
    Yang, Qing
    Song, Jiaqi
    Yu, Wenhui
    Cheng, Pengfei
    Cheng, Liming
    Gong, Yongsheng
    Fu, Xiangning
    Sun, Hui
    FEBS JOURNAL, 2020, 287 (04) : 783 - 799
  • [38] Immune-related adverse events in non-small cell lung cancer: Occurrence, mechanisms and therapeutic strategies
    Lin, Xuwen
    Xie, Mei
    Yao, Jie
    Ma, Xidong
    Qin, Lin
    Zhang, Xu-Mei
    Song, Jialin
    Bao, Xinyu
    Zhang, Xin
    Zhang, Yinguang
    Liu, Yiming
    Han, Wenya
    Liang, Yiran
    Jing, Ying
    Xue, Xinying
    CLINICAL AND TRANSLATIONAL MEDICINE, 2024, 14 (03):
  • [39] Immune-mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non-small cell lung cancer patient: A case report
    Makiguchi, Tomonori
    Tanaka, Hisashi
    Kamata, Kosuke
    Taima, Kageaki
    Kurose, Akira
    Tasaka, Sadatomo
    THORACIC CANCER, 2021, 12 (20) : 2811 - 2814
  • [40] Immune-related toxicities in advanced non-small cell lung cancer: a two-centre experience
    Mithra, S.
    Dancey, G.
    Durga, T.
    Islam, M.
    Ibikunle, Y.
    LUNG CANCER, 2020, 139 : S55 - S55
12345